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Abstract:  131 
Elevated blood pressure is the leading heritable risk factor for cardiovascular disease 132 
worldwide. We report genetic association of blood pressure (systolic, diastolic, pulse 133 
pressure) among UK Biobank participants of European ancestry with independent replication 134 
in other cohorts, leading to discovery and validation of 107 novel loci. We also identify new 135 
independent variants at 16 previously reported blood pressure loci. Combined with results 136 
from a range of in-silico functional analyses and wet bench experiments, our findings highlight 137 
new biological pathways for blood pressure regulation enriched for genes expressed in 138 
vascular tissues and identify potential therapeutic targets for hypertension. Results from 139 
genetic risk score models raise the possibility of a precision medicine approach through early 140 
lifestyle intervention to offset the impact of blood pressure raising variants on future 141 
cardiovascular disease risk.  142 
 143 
 144 
 145 
  146 
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Elevated blood pressure is a strong, heritable and modifiable driver of risk for stroke and 147 
coronary artery disease and a leading cause of global mortality and morbidity1,2.  In most 148 
populations blood pressure rises with age and by older ages over 50% of the population has 149 
hypertension3,4. Raised blood pressure is heritable and arises from a complex interplay of 150 
lifestyle exposures and genetic background5-8. To date, studies including genome-wide meta-151 
analyses of up to 2.5 million HapMap imputed variants across multiple studies, and analyses 152 
of bespoke or exome content, have identified 163 genetic variants of mostly modest or weak 153 
effect on blood pressure at 122 loci9-13. Here, we report association analyses between three 154 
blood pressure traits (systolic, diastolic and pulse pressure) and genetic variants among the 155 
first ~150,000 UK Biobank participants, with independent replication in large international 156 
consortia and other cohorts, providing new biological insights into blood pressure regulation. 157 
 158 
UK Biobank is a prospective cohort study of 500,000 men and women aged 40-69 years with 159 
extensive baseline phenotypic measurements according to a standardized protocol (including 160 
blood pressure by a semi-automated device), stored biological samples (including DNA)14, and 161 
follow-up by electronic health record linkage15. Participants were genotyped using a 162 
customised array (including GWAS and exome content) and with genome-wide imputation 163 
based on 1000 Genomes and UK10K sequencing data16,17. 164 
 165 
Our study design is summarised in Fig. 1. Briefly, of the 152,249 UK Biobank participants with 166 
genotype data, after quality measures and exclusions (see Methods Online), we study 167 
140,886 unrelated individuals of European ancestry with two seated clinic blood pressure 168 
measurements (Supplementary Table 1). We carry out genome-wide association study 169 
(GWAS) analyses of systolic, diastolic and pulse pressure using single-variant linear regression 170 
under an additive model, based on ~9.8 million single nucleotide variants (SNVs) with minor 171 
allele frequency (MAF) >1% and imputation quality score (INFO) >0.1. We then consider for 172 
replication SNVs with P <1x10-6 and take forward the sentinel SNV (i.e. with lowest P-value) 173 
at each locus, with a locus being defined by linkage disequilibrium (LD) r2 < 0.2, within a 1Mb 174 
interval. We similarly analyse exome content for variants with MAF >0.01%, including rare 175 
variants, taking into replication the sentinel SNV (P < 1x10-5) from loci that are non-176 
overlapping (r2 <0.2) with the GWAS findings. Overall we took the sentinel SNVs from 240 loci 177 
into replication (r2 < 0.2 and >500kb from previously reported blood pressure SNVs and not 178 
annotated to previously reported blood pressure genes): 218 from GWAS and 22 from the 179 
exome analysis (GWAS variants from an additional 17 novel loci could not be taken into 180 
replication due to the absence of the variant or a proxy in the replication resources 181 
(Supplementary Tables 2 and 3).  182 
 183 
The replication resources comprise a large BP meta-analysis consortium and further cohorts 184 
with 1000 Genomes data for the GWAS findings (Supplementary Table 4), and large blood 185 
pressure exome consortia meta-analyses, both with individuals of European ancestry. We use 186 
P <5x10-8 to denote genome-wide significance in the combined (discovery and replication) 187 
meta-analyses, also requiring significant association (P < 0.01) in the replication data alone 188 
and concordant direction of effect. Additionally, we take forward for replication potential 189 
secondary signals at 51 previously reported blood pressure loci (excluding the HLA region).  190 
To better understand the functional consequences of our new discoveries as well as 191 
previously reported variants, we carry out a series of in silico investigations including 192 
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expression Quantitative Trait Locus (eQTL) analyses, tissue and DNASE hypersensitivity site 193 
enrichment and pathway analyses (Supplementary Fig. 1).  We also test for long-range 194 
regulatory interactions (Hi-C) and investigate metabolomics signatures associated with our 195 
sentinel SNVs. Finally, we undertake experimental analysis of gene expression in relevant 196 
vascular tissue for selected putative functional SNVs.  197 
RESULTS 198 
Discovery and validation of genetic variants at novel loci 199 
Of the 240 not previously reported loci taken forward to replication, we validate 107 novel 200 
loci at P < 5x10-8, of which 102 derive from the GWAS analysis replicated and meta-analysed 201 
in a total of 330,956 individuals (Table 1a; Fig. 2a-c; Supplementary Fig. 2a), and a further 202 
five are from the exome analysis validated in a total of 422,604 individuals from the combined 203 
meta-analysis (Table 1b and Supplementary Fig. 2b; Supplementary Tables 5 and 6). Most 204 
SNVs also show association with hypertension in the UK Biobank data, for example 93 of the 205 
107 novel sentinel SNVs are nominally significant (P < 0.01) (Supplementary Table 7). 206 
 207 
Our results for systolic, diastolic and pulse pressure are shown in Figs. 2a,b,c respectively. The 208 
most significant association signal for systolic pressure, which rises with age is with 209 
rs112184198 near PAX2 (P =3.6 x 10-18); for diastolic pressure, which plateaus in middle age, 210 
with rs76326501 near METTL21A- ACO16735.1 (P =3.6 x 10-18); and rs3889199 near FGGY (P 211 
= 1.8 X 10-24) for pulse pressure, which increases with age and arterial stiffening18. However, 212 
as blood pressure traits are highly correlated, we unsurprisingly report considerable overlap 213 
in these findings (Supplementary Fig. 3). Many loci are associated with more than one blood 214 
pressure trait at genome-wide significance. For example, in the combined meta-analysis, 24 215 
novel loci are associated with both systolic and diastolic pressure, 11 with both systolic and 216 
pulse pressure, one locus with both diastolic and pulse pressure and four loci (NADK-CPSF3L, 217 
GTF2B, METTL21A-AC079767.3 and PAX2) are associated with all three traits (Fig. 1d). We 218 
further note that many of the pulse pressure associated SNVs have opposing directions of 219 
effect for systolic and diastolic pressure, and are less likely to have strong associations with 220 
hypertension. 221 
 222 
After conditional analysis on the sentinel SNV we identify five validated secondary SNVs in 223 
novel regions that are independently associated with blood pressure traits (Table 2a; 224 
Supplementary Table 8). We also note the existence of a rare validated potential secondary 225 
variant at the NOX4 locus (rs56061986, MAF = 0.3%); although we do not claim this as an 226 
independent signal after conditioning on the sentinel variant, its relatively large effect on 227 
blood pressure remains (Supplementary Table 8). The contribution of our novel loci increases 228 
the percentage trait variance explained by ~1%, e.g. compared with 2.59% for previously 229 
reported SNVs alone, taken together, the novel and previously reported SNVs explain 3.56% 230 
of variance for systolic blood pressure, in an independent population. 231 
 232 
For the first time in GWAS we report a signal at the angiotensin converting enzyme (ACE) locus 233 
(P = 6.8 x 10-14), from the renin-angiotensin system, a pathway which is targeted by current 234 
blood pressure treatments (ACE-inhibitors), as well as several other signals at known 235 
hypertension drug targets. These include CACNA2D2 (rs743757, P = 2.4 x 10-10) targeted by 236 
calcium channel blockers, MME (rs143112823 in the RP11-439C8.2 locus, P = 1.4 x 10-14) 237 
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targeted by omapatrilat for treating hypertension, ADRA2B (rs2579519 in the GPAT2-238 
FAHD2CP locus, P = 4.8 x 10-12) targeted by beta blockers, SLC14A2 (rs7236548, P = 2.0 x 10-239 
18) targeted by the hypertension drug nifedipine, and phosphodiesterase 5A (PDE5A; 240 
rs66887589, P = 3.4 x 10-15) targeted by sildenafil for treating pulmonary hypertension.  241 
 242 
Additionally, we evaluate our novel SNVs, where available, in cohorts of non-European 243 
ancestry12,13, while recognising that these analyses are likely underpowered (Supplementary 244 
Table 9). For the GWAS SNVs, we find concordance in direction of effect (P <0.05) for all three 245 
blood pressure traits for individuals of East Asian ancestry, and for diastolic pressure for South 246 
Asian ancestry. For the exome analyses, we find concordance in direction of effect among 247 
individuals of Hispanic ancestry. Despite small numbers, these findings point to cosmopolitan 248 
effects for many of the blood pressure associated variants.  249 
 250 
A PhenoScanner19 search revealed that 27 of our 107 novel sentinel SNVs (or proxies; r2 ≥ 0.8) 251 
exhibit genome-wide significant associations (Fig. 3a) with other traits, including 252 
cardiovascular outcomes (e.g. coronary artery disease, myocardial infarction), cardiovascular 253 
risk factors (e.g. lipids, height, body mass index) and non-cardiovascular traits (e.g. lung 254 
function, cancer, Alzheimer’s). While some of these associations may reflect pleiotropy, for 255 
others such as coronary artery disease it is likely from evidence from trials that elevated blood 256 
pressure lies on the causal pathway20.  257 
Associations at previously reported loci 258 
In the conditional analyses, we identify 22 secondary SNVs (17 common, one rare and four 259 
low-frequency variants) that are conditionally independent of the blood pressure associated 260 
SNVs at 16 previously reported loci (Table 2b; Supplementary Tables 10 and 11). One rare 261 
variant (rs138582164, MAF=0.1%) in the CDH17 locus anticipated to act as an exonic 262 
stop/gain mutation at the GEM gene is associated with a relatively large effect on pulse 263 
pressure (3.5 mm Hg per allele copy, Table 2b). At three previously reported loci (EBF1, 264 
PDE3A, JAG1) we identify multiple independent secondary SNVs in addition to the previously 265 
reported SNVs (Supplementary Table 10).  266 
 267 
We confirm association (P < 0.01) in the UK Biobank data for 119 of the 122 previously 268 
reported blood pressure loci (160 of 163 SNVs) for one or more blood pressure traits (Fig. 2 269 
a-c; Supplementary Table 12). Only three previously reported SNVs do not replicate in UK 270 
Biobank, one of which (rs11066280, RPL6-ALDH1) was identified from a GWAS of East Asian 271 
ancestry21 and may have ancestry-specific effects. 272 
We also examine findings for low-frequency and rare gene mutations previously reported to 273 
be associated with monogenic hypertension disorders22 and included on the UK Biobank gene 274 
array. Due to a lack of power for testing rare variants, even within a large single study, only 275 
one monogenic mutation (rs199469624; KLH3; MAF=0.02%) shows nominally significant 276 
association (P < 0.05; Supplementary Table 13). However, we do detect a large effect of this 277 
rare variant (8.2 mm Hg and 5.6 mm Hg per allele for systolic and pulse pressure respectively) 278 
within the UK Biobank data. 279 
 280 
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Functional analyses  281 
We annotate the 107 novel loci to 212 genes (based on LD r2 ≥0.8) and seek putative function 282 
from in silico analyses of our novel and previously reported loci, as well as undertaking gene 283 
expression experiments for selected SNVs in relevant vascular tissue. Of the 107 novel 284 
sentinel SNVs only three are Indels, all other variants are single nucleotide polymorphisms 285 
(SNPs). We identify non-synonymous SNVs at 13 of the 107 novel loci, including three non-286 
synonymous novel sentinel SNVs (rs1250259 at FN1 locus, rs78648104 at TFAP2D and 287 
rs7127805 at CRACR2B locus) (Supplementary Table 14). Furthermore three of the 13 novel 288 
loci contain non-synonymous SNVs that are predicted to be damaging in TFAP2D 289 
(rs78648104), NOX4 (rs56061986, see above) and CCDC141 (rs17362588, reported to be 290 
associated with heart rate23) (Fig. 3a). Beyond the coding regions we identify 29 novel 291 
associated SNVs in 3’UTRs which are predicted to significantly weaken or cause loss of miRNA 292 
regulation by altering the recognition motif in seven genes, and strengthen or create target 293 
sites for miRNA binding in 13 genes (Supplementary Table 14). 294 
Our expression Quantitative Trait locus (eQTL) analysis shows that many novel loci contain 295 
variants with eQTLs across a range of different tissues (Supplementary Table 15). Of the 107 296 
novel loci, 59 contain variants with eQTLs in at least one tissue. We observe arterial tissue as 297 
the tissue having the largest number of loci with eQTLs (Supplementary Fig. 4). Our follow-298 
up targeted in-silico analysis reveals six novel loci with eQTLs in arterial tissue (Supplementary 299 
Table 14). For example, the GTEx tibial artery eQTL in SF3A3 (rs4360494) shows strong in silico 300 
supporting evidence, including an arterial DNase I site within which the major C allele removes 301 
a predicted AP-2 binding site (Supplementary Fig. 5). Hence we prioritised this gene for in 302 
vitro functional analysis (see below).  303 
By considering all loci together from both novel and previously reported loci, our analysis 304 
using DEPICT identifies enrichment of expression across 31 tissues and cells (Supplementary 305 
Fig.6; Supplementary Table 16), with greatest enrichment in the arteries (P = 1.9 x 10-6, false 306 
discovery rate (FDR) < 1%). We use FORGE to investigate and identify significant (FDR, P <0.05) 307 
cell type specific enrichment within DNase I hypersensitive sites in a range of tissues including 308 
dermal and lung microvascular endothelial cell types, and cardiac fibroblasts (Supplementary 309 
Fig. 7). For a set of curated candidate regulatory SNVs from novel loci (see Supplementary 310 
Methods), widespread enrichment is found in microvascular endothelium, aortic smooth 311 
muscle, aortic fibroblasts, vascular epithelium, heart and skin (Supplementary Fig. 7). In 312 
addition, we identify significant enrichment of histone marks in a wide range of cell types, 313 
including strong enrichment seen for H3K4Me3 (an activating modification found near 314 
promoters) marks in umbilical vein endothelial cells (HUVEC) (Supplementary Fig. 8). To 315 
explore expression at the level of cardiovascular cell types specifically, we use Fantom5 316 
reference transcript expression data (see Methods Online) to cluster the 212 genes annotated 317 
to our 107 novel loci according to tissue specificity (Supplementary Fig. 9), with the 318 
significantly clustered genes forming four tissue-specific clusters, including a vascular smooth 319 
muscle cell (VSMC) and fibroblast cluster, an endothelial cell cluster (including probable 320 
endothelial cells in highly vascularised tissues), and a combined vascular cell cluster.    321 
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Additionally, Ingenuity pathway analysis and upstream transcriptional analysis show 322 
enrichment of canonical pathways implicated in cardiovascular disease, including those 323 
targeted by antihypertensive drugs, such as the alpha-adrenergic, CXCR4, endothelin 324 
signalling and angiotensin receptor pathways (Supplementary Table 17). In keeping with 325 
vascular mediation of genetic influence we identify diphenyleneiodonium, an inhibitor of 326 
flavin-containing oxidases, including NAD(P)H oxidase, which is reported to reverse 327 
endothelial dysfunction (and hypertension) in a rat model24.  328 
In order to identify long range target genes of non-coding variants, we use chromatin 329 
interaction (Hi-C) data from HUVEC, as enhancers and silencers often form chromatin loops 330 
with their target promoter. In most loci the strongest promoter interaction involves a gene in 331 
high LD with the SNV but for 21 loci we find a distal potential target gene (Supplementary 332 
Table 14). Ingenuity pathway analysis of the distal genes shows the greatest enrichment in 333 
regulators of cardiac hypertrophy. 334 
We further evaluate pleiotropy using the Genomic Regions Enrichment of Annotations Tool 335 
(GREAT) to study enrichment of mouse phenotype and human disease ontology terms across 336 
all our novel and previously reported loci. These highlight cardiovascular system 337 
abnormalities and vascular disease as the most highly enriched terms (Fig. 3b & 3c).  338 
Collectively evidence from eQTLs, DEPICT, DNase I sites, histone marks, Hi-C data and 339 
ontological analyses indicates predominant vascular and cardiovascular tissue involvement 340 
for genes within the blood pressure associated loci. For example, aggregating all loci together 341 
in the DEPICT analysis, we observe greatest enrichment in arterial tissue, which has the largest 342 
proportion of novel loci having variants with eQTLs. 343 
We also look for association of our validated sentinel SNVs with metabolomic signatures. 344 
Three novel SNVs within the NOX4, KCNH4 and LHFPL2 loci show significant associations 345 
(family-wise error rate < 5%) with lipoprotein sub-fractions from 1H Nuclear Magnetic 346 
Resonance (NMR) spectroscopy analysis of 2,000 Airwave study samples (Supplementary 347 
Tables 18 and 19). The results for these variants suggest a link between blood pressure 348 
regulation and lipid metabolism. Eleven SNVs (including at LHFPL2 locus) show association 349 
(family wise error rate < 5%) with metabolites in blood or urine from the publicly available 350 
“Metabolomics GWAS Server” resource based on mass spectrometry25,26(Supplementary 351 
Table 19), including sugar acids, sphingolipids, fatty acids, glycerophospholipids, organic acids 352 
and benzene derivatives.   353 
Several genes and variants with putative function are highlighted in our in silico analysis as 354 
having biological support (e.g. eQTLs or nsSNVs) and those with novelty and tractability to 355 
laboratory investigation (e.g. expression in available tissue models) are prioritized. Variants 356 
in three genes are selected for experimental testing and successfully genotyped, each for at 357 
least 100 samples. We select ADAMTS7 due to strong biological support (e.g. mouse knockout 358 
phenotype), SF3A3 due to eQTLs and NOX4 as it contains a rare nsSNV in addition to common 359 
variant associations. We use quantitative polymerase chain reaction (qPCR) to study the 360 
impact of these sentinel variants on gene expression in human vascular smooth muscle 361 
(VSMCs) and endothelial cells (ECs) (see Methods Online). For SF3A3, the major C allele of 362 
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sentinel variant rs4360494 associated with increased pulse pressure is also associated with 363 
SF3A3 expression in human VSMCs, although this SNV is not related to expression in 364 
endothelial cells (Supplementary Fig. 10a); and the T allele of SNV rs62012628 in ADAMTS7, 365 
associated with lower diastolic pressure, is associated with reduced ADAMTS7 expression in 366 
human VSMCs (Supplementary Fig. 10b). Moreover, we find that the minor A allele of 367 
sentinel SNV rs2289125 at the NOX4 locus correlates with increased NOX4 expression in ECs 368 
though not VSMCs (Supplementary Fig. 10c). Our study thus finds evidence for novel cis-369 
eQTLs in ADAMTS7 and NOX4 in addition to validating the previously reported GTEx eQTL in 370 
SF3A3, and supports the vascular expression of these genes.   371 
Genetic risk of increased blood pressure, hypertension and cardiovascular outcomes 372 
We create an unbiased genetic risk score (GRS) (Supplementary Table 20) to evaluate, in an 373 
independent cohort (Airwave, see Methods Online), the impact of the combination of our 374 
validated novel and previously reported loci on blood pressure levels and risk of hypertension. 375 
The combination of these blood pressure influencing variants is associated with sex-adjusted 376 
mean systolic pressure that is 9.3 mm Hg (95% CI 6.9 to 11.7 mm Hg, P =1.0 x 10-13) higher at 377 
ages 50 years and over, comparing the upper and lower fifths of the GRS distribution; and an 378 
over two-fold higher risk of hypertension (OR 2.32 95% CI 1.76 to 3.06; P=2.8 x 10-9) (Fig. 4; 379 
Supplementary Table 21). Similar results were obtained from GRS associations with blood 380 
pressure and hypertension within UK Biobank (Supplementary Table 22). In UK Biobank − 381 
based on self-reported health data, record linkage to Hospital Episode Statistics and mortality 382 
follow-up data (Supplementary Table 23) − we show that the GRS is associated with increased 383 
risk of stroke, coronary heart disease and all cardiovascular outcomes, comparing the upper 384 
and lower fifths of the GRS distribution, with sex-adjusted odds ratios of 1.34 (95% CI 1.20 to 385 
1.49, P =1.5×10-7), 1.38 (95% CI 1.30 to 1.47, P= 4.3×10-23) and 1.35 (95% CI 1.27 to 1.42, 386 
P=1.3×10-25) respectively (Fig. 4; Supplementary Table 24).  387 
 388 
DISCUSSION  389 
A key attribute of this study is the combination of a large, single discovery sample with 390 
standardized blood pressure measurement and a dense 1000 Genomes imputation strategy 391 
(UK 10K enhanced 1000G imputation), yielding a high quality dataset of ~9.8 million variants 392 
for study16. This is the largest genetic association analysis for blood pressure to date taking 393 
advantage of major international consortia for parallel replication of common and low-394 
frequency variants, based in total on data from 330,956 individuals and exonic SNVs in a total 395 
of 422,604 individuals27. This strategy resulted in the discovery of 107 robustly validated novel 396 
loci for blood pressure traits. In previous large-scale blood pressure genome-wide association 397 
scans we estimated that an effective doubling of sample size from a discovery cohort of 398 
70,000 to 140,000 individuals with ~2.5 million imputed variants would double the number 399 
of validated loci, resulting in an estimated ~30 additional loci for blood pressure traits27. Here 400 
we find over three times that number, taking advantage of UK Biobank’s standardized 401 
approach to data collection, biobanking, genotyping and enhanced imputation strategy. 402 
Nonetheless, despite its size, our study is still under-powered to find rare variants - the vast 403 
majority of our findings are common variants, with similarly modest or small effect sizes as 404 
for previously reported variants (Supplementary Fig. 11). There may be greater potential for 405 
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identifying rare variants from the future release of genetic data for all 500,000 UK Biobank 406 
participants.  407 
Our findings point to new biology as well as highlighting novel gene regions in systems that 408 
have previously been implicated in the genetics of blood pressure. Several of our novel loci 409 
affect atherosclerosis or vascular remodelling (ADAMTS7, THBS2, CFDP1) and exhibit locus 410 
pleiotropy in prior genome-wide association studies for coronary artery disease or carotid 411 
intimal-media thickness28-30 (Fig. 3a  and Fig. 5). In previous work we have shown that 412 
expression of ADAMTS7 is upregulated and increases vascular smooth muscle cell migration 413 
in response to vascular injury in relation to a distinct coronary artery variant (rs3825807 which 414 
is not in strong LD with our sentinel SNV; r2 = 0.17)31. In endothelial cells ADAMTS7 acts as a 415 
metalloproteinase to cleave thrombospondin-1 encoded by THBS2 which leads to reduced 416 
endothelial cell migration and plays a role in neo-intimal repair in the vessel wall31. Our 417 
functional work indicates that the allele associated with lower diastolic pressure is also 418 
associated with lower ADAMTS7 expression in human vascular smooth muscle cells; this fits 419 
with the murine knockout that exhibits reduced32 atherosclerosis.  At the CFDP1 locus our 420 
sentinel SNV is in high LD (r2 = 0.95) with a variant previously associated with carotid intimal-421 
medial thickness33.  422 
We identify both common and rare variant associations at the novel NADPH oxidase 4 (NOX4) 423 
locus. This oxidase generates reactive oxygen species in the endothelium and may contribute 424 
to salt sensitive hypertension in the kidney and the vasculature34-36. We found that the allele 425 
of the common variant at NOX4 locus correlates with increased tissue specific NOX4 426 
expression in endothelial cells rather than vascular smooth muscle cells (Supplementary 427 
Figure 10c). NOX4 mediates endothelial cell apoptosis and facilitates vascular collagen 428 
synthesis contributing to endothelial dysfunction and arterial stiffness, and may explain the 429 
association with pulse pressure37,38.  430 
We identify several loci containing genes involved in vascular signalling and second 431 
messenger systems such as PDE5A and PDE10A39-41. The phosphodiesterase PDE5A 432 
hydrolyses cyclic GMP and is inhibited by sildenafil which leads to vasodilatation42. This 433 
finding fits with our previous discoveries of a role for gene loci encoding elements of 434 
natriuretic peptide-nitric oxide pathway and guanylate cyclase signalling systems in blood 435 
pressure regulation21,43,44.  Our findings strengthen the case for evaluating the opportunity to 436 
repurpose PDE5A inhibitors for use in hypertension. 437 
The importance of microvascular function is emphasised by the solute carrier transporters 438 
such as SLC14A2 encoding a urea transporter, which has previously been linked to autosomal 439 
dominant Streeten type orthostatic hypotensive disorder45 and blood pressure response to 440 
nifedipine, a calcium channel blocker antihypertensive drug46.  SLC8A1 encodes a sodium 441 
calcium exchanger expressed in cardiomyocytes which alters cardiac contractility and 442 
hypertrophy and shows abnormal blood pressure in SLC8A1 transgenic mice47. Variants at 443 
SLC35F1 have been previously associated with resting heart rate and ventricular dimensions 444 
which could contribute to blood pressure elevation48.  445 
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We also identify loci that are involved in cardiovascular development (GATA2, KIAA1462, 446 
FBN2, FN1 and HAND2) such as fibrillin 2 (FBN2) which overlaps in action with fibrillin 1 in 447 
development of the aortic matrix49-53. In addition, fibronectin expression is increased in 448 
hypertension and in atherosclerosis but it may also play a role in the development of the 449 
heart53-55. 450 
Our analysis validates loci containing genes with prior physiological connection to blood 451 
pressure such as BDNF, FAM208A, and CACNA2D256-58. The neurotrophin Brain Derived 452 
Neurotrophic Factor modulates angiotensin 11 in the brain to elevate blood pressure in 453 
experimental models and higher serum levels correlate with reduced risk of cardiovascular 454 
disease and mortality56. In experimental models FAM208A, which is thought to be a 455 
transcription factor, is a strong candidate for a quantitative trait locus for blood pressure58. 456 
The gene CACNA2D2 encodes a subunit of the L-type calcium channel that is most abundantly 457 
expressed in the atrium and in neurones and may be a target for negatively chronotropic and 458 
inotropic calcium channel antagonists which reduce blood pressure59.  459 
This is the first time long range genomic interactions have been sought using Hi-C for blood 460 
pressure, where the promoter region has a strong chromatin interaction with a novel SNV. 461 
One such gene is EPAS1, which is ~200kb away from the SNV (rs11690961). It encodes 462 
hypoxia-inducible factor 2alpha, which affects catecholamine homeostasis, protects against 463 
heart failure and mutations in the gene are associated with pulmonary hypertension60. 464 
Another gene is INHBA, 1.3Mb away from the SNV (rs12531683), which is elevated in 465 
pulmonary hypertension and contributes to vascular remodelling by inducing expression of 466 
endothelin-1 and plasminogen activator inhibitor-1 in pulmonary smooth muscle cells61. 467 
Our observation that the blood pressure genetic risk score is associated with 9-10 mm Hg 468 
higher blood pressure at age 50+ years when comparing the top vs bottom fifths of the 469 
distribution in an independent population has potential clinical and public health implications. 470 
Were the genetic risk score to be measured at birth or in childhood, there would be the 471 
possibility of adopting an early precision medicine approach to risk management through 472 
lifestyle intervention (i.e. reduced sodium intake, increased potassium intake, maintenance 473 
of optimal weight, low adult alcohol consumption and regular exercise)62-64. Studies of non-474 
pharmacologic approaches to blood pressure control indicate that we could achieve 10 mm 475 
Hg or more reduction in systolic blood pressure through lifestyle measures alone65. This would 476 
be sufficient to offset the genetic influence on the rise of blood pressure from young 477 
adulthood to middle age and reduce the resultant high prevalence of hypertension at older 478 
ages. Such a precision medicine approach could thus mitigate the risk of future cardiovascular 479 
disease among people at high genetic risk of raised blood pressure. 480 
We describe 107 novel validated loci for blood pressure offering new biology, identifying 481 
potential new therapeutic targets and raising the possibility of a precision medicine approach 482 
to modify risk of hypertension and cardiovascular outcomes.  In total this brings the number 483 
of combined novel and previously reported loci for blood pressure traits to 229, representing 484 
a major advance in our understanding of the genetic architecture of blood pressure.  485 
  486 
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Table 1: Association results for the sentinel variant from each novel validated locus from (a) UK Biobank GWAS discovery and (b) UK 716 
Biobank exome discovery. Results are shown for the primary blood pressure trait with most significant association from the combined meta-717 
analysis.  718 
(a) UK Biobank GWAS                         
Sentinel SNV in the locus   UK Biobank discovery Replication Combined 
Locus Chr Pos rsID EA INFO EAF Beta SE P Beta SE P N Beta SE P 
Systolic blood pressure                
NADK-CPSF3L 1 1685921 rs139385870 D 0.99 0.50 -0.394 0.07 1.9x10-8 -0.310 0.07 1.0x10-5 281,890 -0.352 0.05 1.3x10-12 
CELA2A 1 15798197 rs3820068 A 0.99 0.81 0.497 0.09 2.4x10-8 0.367 0.08 5.3x10-6 310,776 0.425 0.06 1.1x10-12 
GTF2B 1 89360158 rs10922502 A 0.99 0.62 -0.475 0.07 4.7x10-11 -0.307 0.06 2.0x10-6 323,666 -0.382 0.05 2.2x10-15 
FOSL2 2 28635740 rs7562 T 0.98 0.52 0.365 0.07 2.2x10-7 0.182 0.06 3.7x10-3 319,942 0.263 0.05 1.9x10-8 
PRKD3 2 37517566 rs13420463 A 1.00 0.77 0.504 0.08 1.4x10-9 0.244 0.07 7.3x10-4 330,307 0.356 0.05 7.0x10-11 
METTL21A-AC079767.3 2 208526140 rs55780018 T 0.97 0.54 -0.426 0.07 1.7x10-9 -0.360 0.07 5.1x10-8 304,567 -0.391 0.05 5.9x10-16 
RYK 3 134000025 rs9859176 T 0.97 0.40 0.419 0.07 6.4x10-9 0.248 0.06 9.6x10-5 322,428 0.322 0.05 1.3x10-11 
NPNT 4 106911742 rs13112725 C 1.00 0.76 0.418 0.08 3.1x10-7 0.450 0.08 9.4x10-9 306,370 0.435 0.06 1.5x10-14 
TMEM161B 5 87514515 rs10059921 T 0.98 0.08 -0.644 0.13 5.9x10-7 -0.417 0.12 7.9x10-4 298,543 -0.526 0.09 4.0x10-9 
FBN2 5 127868199 rs6595838 A 0.93 0.30 0.483 0.08 2.0x10-10 0.236 0.07 4.5x10-4 328,401 0.344 0.05 7.6x10-12 
CASC15 6 22130601 rs6911827 T 0.99 0.45 0.433 0.07 8.2x10-10 0.190 0.06 2.1x10-3 326,471 0.296 0.05 2.0x10-10 
TFAP2D 6 50683009 rs78648104 T 1.00 0.92 -0.664 0.13 1.2x10-7 -0.329 0.11 4.0x10-3 305,426 -0.481 0.08 1.3x10-8 
MKLN1 7 131059056 rs13238550 A 1.00 0.40 0.486 0.07 9.4x10-12 0.212 0.06 7.1x10-4 325,647 0.331 0.05 1.9x10-12 
HIPK2 7 139463264 rs1011018 A 0.98 0.20 -0.441 0.09 6.1x10-7 -0.244 0.08 1.6x10-3 325,110 -0.329 0.06 1.5x10-8 
ZFAT 8 135612745 rs894344 A 1.00 0.60 -0.384 0.07 6.8x10-8 -0.163 0.06 8.2x10-3 329,834 -0.258 0.05 3.2x10-8 
PAX2 10 102604514 rs112184198 A 0.99 0.10 -0.826 0.12 7.8x10-13 -0.532 0.10 1.3x10-7 323,791 -0.659 0.08 3.6x10-18 
MCF2L 13 113636156 rs9549328 T 1.00 0.23 0.440 0.08 1.5x10-7 0.218 0.08 3.9x10-3 313,787 0.318 0.06 1.5x10-8 
FERMT2 14 53377540 rs9888615 T 0.99 0.29 -0.427 0.08 3.5x10-8 -0.236 0.07 4.3x10-4 326,235 -0.318 0.05 3.5x10-10 
PPP2R5E 14 63928546 rs8016306 A 0.99 0.80 0.454 0.09 2.5x10-7 0.250 0.07 7.9x10-4 329,869 0.335 0.06 3.7x10-9 
ABHD17C 15 81013037 rs35199222 A 0.99 0.45 0.353 0.07 5.7x10-7 0.298 0.06 1.7x10-6 323,407 0.322 0.05 5.2x10-12 
CFDP1 16 75331044 rs11643209 T 0.98 0.42 -0.481 0.07 1.8x10-11 -0.222 0.06 6.3x10-4 309,242 -0.339 0.05 1.8x10-12 
CRK 17 1333598 rs12941318 T 0.99 0.49 -0.317 0.07 6.2x10-6 -0.226 0.07 6.9x10-4 299,739 -0.269 0.05 2.5x10-8 
ACOX1 17 73949045 rs2467099 T 1.00 0.22 -0.423 0.08 4.5x10-7 -0.216 0.07 3.6x10-3 326,401 -0.307 0.06 3.3x10-8 
Diastolic blood pressure                       
chr1mb25 1 25030470 rs6686889 T 0.99 0.25 0.231 0.05 3.7x10-7 0.143 0.04 9.1x10-4 322,575 0.185 0.03 3.6x10-9 
DNM3 1 172357441 rs12405515 T 0.98 0.56 -0.219 0.04 4.1x10-8 -0.118 0.04 1.6x10-3 328,543 -0.165 0.03 1.4x10-9 
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GPATCH2 1 217718789 rs12408022 T 0.97 0.26 0.226 0.05 5.9x10-7 0.172 0.04 6.7x10-5 320,983 0.198 0.03 2.4x10-10 
CDC42BPA 1 227252626 rs10916082 A 1.00 0.73 -0.222 0.04 5.3x10-7 -0.135 0.04 1.5x10-3 327,636 -0.177 0.03 8.4x10-9 
WNT3A 1 228191075 rs2760061 A 0.98 0.47 0.235 0.04 3.7x10-9 0.225 0.04 1.1x10-8 312,761 0.230 0.03 2.1x10-16 
SDCCAG8 1 243471192 rs953492 A 0.99 0.46 0.293 0.04 1.2x10-13 0.153 0.04 4.6x10-5 325,253 0.220 0.03 7.4x10-16 
ADCY3 2 25139596 rs55701159 T 0.98 0.89 0.382 0.06 1.1x10-9 0.193 0.06 1.6x10-3 321,052 0.285 0.04 7.2x10-11 
SLC8A1 2 40567743 rs4952611 T 0.95 0.58 -0.200 0.04 8.0x10-7 -0.114 0.04 4.6x10-3 309,395 -0.157 0.03 4.0x10-8 
AC016735.1 2 43167878 rs76326501 A 0.98 0.91 0.426 0.07 4.3x10-10 0.413 0.07 1.5x10-9 318,127 0.419 0.05 3.6x10-18 
GPAT2-FAHD2CP 2 96675166 rs2579519 T 1.00 0.63 -0.259 0.04 1.7x10-10 -0.137 0.04 6.7x10-4 311,557 -0.197 0.03 4.8x10-12 
TEX41 2 145646072 rs1438896 T 1.00 0.30 0.288 0.04 2.1x10-11 0.187 0.04 4.3x10-6 329,278 0.234 0.03 2.0x10-15 
CCDC141 2 179786068 rs79146658 T 1.00 0.91 -0.375 0.07 5.8x10-8 -0.245 0.07 4.2x10-4 321,318 -0.311 0.05 2.4x10-10 
TMEM194B 2 191439591 rs7592578 T 0.99 0.19 -0.271 0.05 8.9x10-8 -0.212 0.05 1.7x10-5 304,672 -0.240 0.04 9.5x10-12 
TNS1 2 218668732 rs1063281 T 0.98 0.60 -0.231 0.04 1.2x10-8 -0.172 0.04 1.4x10-5 315,354 -0.200 0.03 1.3x10-12 
CAMKV-ACTBP13 3 49913705 rs36022378 T 0.99 0.80 -0.265 0.05 6.3x10-8 -0.140 0.05 3.9x10-3 319,983 -0.202 0.03 4.7x10-9 
CACNA2D2 3 50476378 rs743757 C 0.99 0.14 0.313 0.06 2.9x10-8 0.184 0.05 5.1x10-4 328,836 0.245 0.04 2.4x10-10 
FAM208A 3 56726646 rs9827472 T 1.00 0.37 -0.207 0.04 3.6x10-7 -0.148 0.04 1.7x10-4 323,058 -0.177 0.03 4.3x10-10 
RP11-439C8.2 3 154707967 rs143112823 A 0.97 0.09 -0.484 0.07 2.9x10-12 -0.295 0.08 2.3x10-4 297,343 -0.403 0.05 1.4x10-14 
SENP2 3 185317674 rs12374077 C 1.00 0.35 0.203 0.04 8.3x10-7 0.127 0.04 1.2x10-3 327,513 0.163 0.03 9.2x10-9 
PDE5A 4 120509279 rs66887589 T 1.00 0.52 -0.296 0.04 5.7x10-14 -0.140 0.04 2.1x10-4 324,397 -0.215 0.03 3.4x10-15 
POC5 5 75038431 rs10078021 T 0.99 0.63 -0.223 0.04 4.7x10-8 -0.105 0.04 9.2x10-3 314,172 -0.164 0.03 1.3x10-8 
CPEB4 5 173377636 rs72812846 A 0.97 0.28 -0.232 0.04 1.6x10-7 -0.186 0.04 2.4x10-5 312,601 -0.209 0.03 2.2x10-11 
PKHD1 6 51832494 rs13205180 T 0.97 0.49 0.218 0.04 3.7x10-8 0.123 0.04 1.1x10-3 325,419 0.168 0.03 7.0x10-10 
PDE10A 6 166178451 rs147212971 T 0.98 0.06 -0.421 0.08 2.3x10-7 -0.289 0.09 9.4x10-4 296,010 -0.360 0.06 1.6x10-9 
SLC35F1 6 118572486 rs9372498 A 0.98 0.08 0.459 0.07 5.4x10-10 0.231 0.07 5.6x10-4 330,625 0.334 0.05 1.8x10-11 
SNX31 8 101676675 rs2978098 A 0.99 0.54 0.212 0.04 6.9x10-8 0.122 0.04 1.4x10-3 324,424 0.165 0.03 1.5x10-9 
RP11-273G15.2 8 144060955 rs62524579 A 1.00 0.53 -0.202 0.04 2.8x10-7 -0.140 0.05 2.2x10-3 268,645 -0.175 0.03 3.8x10-9 
MTAP 9 21801530 rs4364717 A 0.99 0.55 -0.218 0.04 3.5x10-8 -0.136 0.04 2.9x10-4 327,173 -0.175 0.03 1.3x10-10 
BDNF 11 27728102 rs11030119 A 1.00 0.31 -0.211 0.04 7.0x10-7 -0.119 0.04 3.3x10-3 330,002 -0.163 0.03 2.9x10-8 
MYEOV 11 69079707 rs67330701 T 0.89 0.09 -0.415 0.07 7.8x10-9 -0.314 0.08 3.8x10-5 276,760 -0.367 0.05 2.1x10-12 
RP11-321F6.1 15 66869072 rs7178615 A 1.00 0.37 -0.207 0.04 3.8x10-7 -0.152 0.04 1.0x10-4 318,076 -0.179 0.03 2.6x10-10 
ADAMTS7 15 79070000 rs62012628 T 0.97 0.29 -0.295 0.04 2.1x10-11 -0.147 0.06 7.7x10-3 244,143 -0.238 0.03 5.1x10-12 
chr15mb95 15 95312071 rs12906962 T 0.98 0.68 -0.292 0.04 5.3x10-12 -0.155 0.04 1.5x10-4 319,952 -0.221 0.03 5.6x10-14 
PPL 16 4943019 rs12921187 T 1.00 0.43 -0.203 0.04 3.0x10-7 -0.147 0.04 1.2x10-4 326,469 -0.174 0.03 2.5x10-10 
FBXL19 16 30936743 rs72799341 A 1.00 0.24 0.235 0.05 3.0x10-7 0.139 0.04 1.6x10-3 324,502 0.185 0.03 5.8x10-9 
CMIP 16 81574197 rs8059962 T 0.98 0.42 -0.241 0.04 2.0x10-9 -0.103 0.04 8.5x10-3 319,839 -0.170 0.03 1.3x10-9 
ACE 17 61559625 rs4308 A 0.98 0.37 0.242 0.04 3.2x10-9 0.186 0.04 2.7x10-6 319,394 0.213 0.03 6.8x10-14 
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MAPK4 18 48142854 rs745821 T 0.99 0.76 0.236 0.05 3.2x10-7 0.150 0.04 4.2x10-4 330,954 0.189 0.03 1.4x10-9 
CCNE1 19 30294991 rs62104477 T 0.99 0.33 0.209 0.04 7.1x10-7 0.148 0.04 2.4x10-4 320,347 0.177 0.03 1.2x10-9 
PLCB1 20 8626271 rs6108168 A 0.99 0.25 -0.305 0.05 1.5x10-11 -0.127 0.04 2.9x10-3 327,368 -0.211 0.03 1.1x10-11 
Pulse pressure                       
chr1mb9 1 9441949 rs9662255 A 0.99 0.43 -0.303 0.05 4.7x10-10 -0.130 0.04 3.0x10-3 310,618 -0.207 0.03 1.9x10-10 
SF3A3 1 38455891 rs4360494 C 0.99 0.55 0.332 0.05 5.7x10-12 0.224 0.05 3.6x10-6 282,851 0.278 0.03 3.7x10-16 
RP4-710M16.1-PPAP2B 1 56576924 rs112557609 A 0.99 0.35 0.280 0.05 3.2x10-8 0.187 0.04 1.8x10-5 325,952 0.227 0.03 6.8x10-12 
FGGY 1 59653742 rs3889199 A 0.99 0.71 0.462 0.05 3.3x10-18 0.271 0.05 1.9x10-9 329,486 0.351 0.03 1.8x10-24 
C2orf43 2 20881840 rs2289081 C 0.99 0.36 -0.251 0.05 5.3x10-7 -0.203 0.04 1.7x10-6 329,140 -0.223 0.03 5.5x10-12 
PRKCE 2 46363336 rs11690961 A 1.00 0.88 0.437 0.07 4.2x10-9 0.266 0.07 4.6x10-5 327,847 0.340 0.05 3.9x10-12 
CEP68 2 65283972 rs74181299 T 0.99 0.62 0.296 0.05 2.1x10-9 0.181 0.04 2.0x10-5 324,224 0.230 0.03 9.6x10-13 
TCF7L1 2 85491365 rs11689667 T 0.99 0.54 0.256 0.05 1.1x10-7 0.118 0.04 3.8x10-3 330,634 0.176 0.03 1.7x10-8 
FN1 2 216300482 rs1250259 A 0.99 0.74 -0.457 0.05 5.5x10-17 -0.210 0.05 7.7x10-6 325,485 -0.314 0.04 8.7x10-19 
GATA2 3 128201889 rs62270945 T 1.00 0.03 0.861 0.14 2.6x10-9 0.366 0.14 9.5x10-3 279,925 0.607 0.10 1.8x10-9 
PALLD 4 169717148 rs1566497 A 0.98 0.42 0.320 0.05 6.6x10-11 0.173 0.04 4.8x10-5 320,948 0.236 0.03 1.9x10-13 
chr4mb174 4 174584663 rs17059668 C 0.98 0.92 -0.442 0.09 9.0x10-7 -0.245 0.08 2.2x10-3 313,277 -0.332 0.06 2.8x10-8 
LHFPL2 5 77837789 rs10057188 A 0.99 0.46 -0.280 0.05 5.5x10-9 -0.149 0.04 3.3x10-4 325,985 -0.205 0.03 6.7x10-11 
GJA1 6 121781390 rs11154027 T 0.99 0.47 0.311 0.05 1.1x10-10 0.125 0.04 3.7x10-3 316,708 0.207 0.03 1.1x10-10 
ESR1 6 152397912 rs36083386 I 1.00 0.11 0.651 0.08 4.6x10-17 0.289 0.07 1.0x10-5 323,303 0.439 0.05 1.5x10-18 
FNDC1 6 159699125 rs449789 C 1.00 0.14 0.480 0.07 2.2x10-12 0.264 0.06 1.3x10-5 325,584 0.359 0.05 2.4x10-15 
THBS2 6 169587103 rs1322639 A 1.00 0.78 0.433 0.06 7.7x10-14 0.230 0.05 3.4x10-6 319,866 0.316 0.04 4.8x10-17 
SUGCT 7 40447971 rs76206723 A 0.99 0.10 -0.405 0.08 2.6x10-7 -0.305 0.07 3.8x10-6 328,162 -0.346 0.05 7.4x10-12 
SLC20A2 8 42324765 rs2978456 T 1.00 0.55 -0.253 0.05 1.3x10-7 -0.130 0.05 4.4x10-3 304,964 -0.188 0.03 1.2x10-8 
TRAPPC9 8 141060027 rs4454254 A 1.00 0.63 -0.320 0.05 9.4x10-11 -0.217 0.04 2.9x10-7 330,022 -0.261 0.03 5.1x10-16 
SCAI 9 127900996 rs72765298 T 0.98 0.87 -0.392 0.07 5.9x10-8 -0.358 0.07 8.6x10-8 316,271 -0.374 0.05 2.7x10-14 
KIAA1462 10 30317073 rs9337951 A 0.94 0.34 0.301 0.05 7.6x10-9 0.262 0.05 5.5x10-8 299,646 0.280 0.04 2.5x10-15 
ARHGAP12 10 32082658 rs10826995 T 0.99 0.71 -0.317 0.05 2.2x10-9 -0.133 0.05 3.9x10-3 327,373 -0.212 0.03 1.1x10-9 
PRDM11 11 45208141 rs11442819 I 1.00 0.11 -0.412 0.07 3.8x10-8 -0.185 0.06 3.3x10-3 326,483 -0.279 0.05 7.1x10-9 
NOX4 11 89224453 rs2289125 A 0.98 0.21 -0.481 0.06 3.1x10-16 -0.293 0.05 2.9x10-8 307,682 -0.377 0.04 9.1x10-22 
CEP164 11 117283676 rs8258 T 1.00 0.38 0.341 0.05 5.3x10-12 0.157 0.04 2.4x10-4 327,038 0.236 0.03 2.9x10-13 
CCDC41 12 94880742 rs139236208 A 0.97 0.10 -0.442 0.08 5.7x10-8 -0.288 0.08 2.8x10-4 291,244 -0.363 0.06 1.6x10-10 
RP11-61O1.1 14 98587630 rs9323988 T 0.98 0.63 -0.291 0.05 5.6x10-9 -0.156 0.04 2.0x10-4 327,551 -0.212 0.03 4.1x10-11 
VAC14 16 70755610 rs117006983 A 0.46 0.01 1.448 0.30 9.4x10-7 0.847 0.16 1.8x10-7 250,766 0.986 0.14 4.1x10-12 
CDH13 16 83045790 rs7500448 A 0.98 0.75 0.386 0.06 4.2x10-12 0.288 0.05 1.8x10-9 321,958 0.329 0.04 1.1x10-19 
KIAA0753 17 6473828 rs7226020 T 0.96 0.56 -0.348 0.05 1.3x10-12 -0.175 0.05 1.4x10-4 303,389 -0.256 0.03 2.3x10-14 
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TP53-SLC2A4 17 7571752 rs78378222 T 0.95 0.99 1.530 0.22 8.9x10-12 0.487 0.18 7.9x10-3 294,053 0.904 0.14 1.8x10-10 
KCNH4-HSD17B1 17 40317241 rs79089478 T 0.99 0.97 0.842 0.15 1.2x10-8 0.377 0.13 4.4x10-3 318,326 0.584 0.10 3.1x10-9 
PYY 17 42060631 rs62080325 A 0.98 0.66 -0.260 0.05 3.6x10-7 -0.128 0.05 4.8x10-3 315,689 -0.186 0.03 4.0x10-8 
MRC2 17 60767151 rs740698 T 0.99 0.56 -0.307 0.05 2.1x10-10 -0.161 0.04 2.8x10-4 311,450 -0.228 0.03 3.1x10-12 
SLC14A2 18 43097750 rs7236548 A 0.99 0.18 0.462 0.06 1.1x10-13 0.273 0.05 2.2x10-7 330,075 0.352 0.04 2.0x10-18 
SLC24A3 20 19465907 rs6081613 A 0.99 0.28 0.326 0.05 1.2x10-9 0.213 0.05 8.1x10-6 315,546 0.263 0.04 1.6x10-13 
ARVCF 22 19967980 rs12628032 T 0.99 0.30 0.269 0.05 2.4x10-7 0.216 0.05 3.8x10-6 310,292 0.240 0.03 5.5x10-12 
XRCC6 22 42038786 rs73161324 T 1.00 0.05 0.611 0.11 6.5x10-9 0.380 0.11 3.1x10-4 267,722 0.496 0.07 2.8x10-11 
(b) UK Biobank exome                        
Systolic blood pressure                        
SSPN 12 26438189 rs6487543 A 0.94 0.77 0.345 0.09 5.9x10-5 0.279 0.06 2.1x10-6 244,842 0.300 0.05 6.3x10-10 
Diastolic blood pressure                       
MRAS 3 138119952 rs2306374 T 1.00 0.84 -0.237 0.05 9.3x10-6 -0.155 0.04 9.3x10-5 281,715 -0.184 0.03 7.4x10-9 
Pulse pressure                       
CD34 1 208024820 rs12731740 T 1.00 0.10 -0.360 0.08 5.8x10-6 -0.202 0.05 1.1x10-4 279,078 -0.249 0.04 1.1x10-8 
ZNF638 2 71627539 rs3771371 T 1.00 0.57 -0.223 0.05 4.1x10-6 -0.130 0.03 9.6x10-5 280,285 -0.160 0.03 5.8x10-9 
CRACR2B 11 828916 rs7126805 A 1.00 0.73 0.262 0.05 1.1x10-6 0.184 0.05 4.6x10-4 145,162 0.222 0.04 3.3x10-9 
 719 
Locus: named according to the nearest annotated gene(s); Pos: build 37; EA: effect allele; INFO: imputation quality score from SNPTEST; EAF: effect allele frequency from 720 
discovery data in UK Biobank; Beta: effect estimate from linear regression; SE: Standard Error of effect estimate; P: P-value of association;  N: total sample size analysed; 721 
Note: within the UK Biobank discovery analysis sample size was N=140,882/140,886 for systolic and pulse pressure / diastolic pressure. 722 
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Table 2: Association results for new independent secondary variants identified at (a) novel loci and (b) previously reported blood pressure 723 
loci from either UK Biobank-GWAS or exome discovery. All listed secondary variants were validated in the replication meta-analyses and 724 
passed the conditional test for independence from the (a) sentinel novel variant from Table 1, or (b) previously reported SNVs (see 725 
Supplementary Tables 8 and 10). 726 
Secondary SNV in the locus     UK Biobank discovery Replication Combined 
Locus Chr Pos rsID EA Trait INFO EAF Beta SE P Beta SE P N Beta SE P 
(a) Novel loci from UK Biobank GWAS 
NADK-CPSF3L 1 1254436 rs1886773 A PP 0.99 0.03 -0.743 0.13 2.0x10-8 -0.481 0.15 1.0x10-3 233,789 -0.625 0.10 1.9x10-10 
RP4-710M16.1-PPAP2B 1 56938218 rs6588634 T PP 0.99 0.89 0.403 0.08 2.1x10-7 0.270 0.07 4.7x10-5 329,029 0.326 0.05 1.0x10-10 
FN1 2 216245694 rs34923683 A PP 1.00 0.02 0.837 0.15 4.8x10-8 0.432 0.16 7.7x10-3 285,653 0.646 0.11 6.8x10-9 
TP53-SLC2A4 17 7185062 rs5417 A DBP 0.99 0.57 0.207 0.04 2.1x10-7 0.207 0.04 1.1x10-7 319,299 0.207 0.03 1.1x10-13 
KCNH4-HSD17B1 17 40709867 rs138643143 A PP 0.85 0.07 0.539 0.10 1.4x10-7 0.420 0.15 5.8x10-3 229,161 0.502 0.08 3.3x10-9 
(b) Previously reported loci 
UK Biobank GWAS                           
RNF207 1 6683240 rs14057 A SBP 0.99 0.35 -0.394 0.07 7.5x10-8 -0.235 0.06 2.0x10-4 329,584 -0.303 0.05 2.5x10-10 
FIGN-GRB14 2 165513065 rs34271465 D SBP 1.00 0.41 -0.370 0.07 1.9x10-7 -0.277 0.06 6.9x10-6 328,486 -0.317 0.05 9.9x10-12 
ENPEP 4 111431444 rs33966350 A SBP 1.00 0.01 1.742 0.31 2.6x10-8 1.525 0.41 1.8x10-4 216,630 1.661 0.25 2.1x10-11 
GUCY1A3-GUCY1B3 4 156406054 rs146853253 D PP 0.99 0.16 0.457 0.06 1.7x10-12 0.212 0.06 1.4x10-4 322,302 0.316 0.04 6.9x10-14 
EBF1 5 158220193 rs31864 A PP 0.99 0.55 0.307 0.05 1.9x10-10 0.132 0.04 1.5x10-3 326,557 0.206 0.03 5.5x10-11 
EBF1 5 158448401 rs888987 C DBP 0.96 0.37 0.208 0.04 4.4x10-7 0.111 0.04 7.1x10-3 311,814 0.160 0.03 4.3x10-8 
PDE3A 12 19979881 rs10841376 C SBP 0.99 0.76 0.261 0.08 1.6x10-3 0.362 0.07 5.1x10-7 327,370 0.319 0.05 4.5x10-9 
PDE3A 12 20230639 rs10770612 A PP 1.00 0.80 0.378 0.06 2.5x10-10 0.259 0.05 1.8x10-6 311,586 0.313 0.04 6.9x10-15 
PDE3A 12 20368269 rs60691990 T DBP 0.98 0.65 0.344 0.04 1.4x10-16 0.223 0.04 7.4x10-8 323,722 0.283 0.03 5.0x10-22 
TBX5-TBX3 12 115928440 rs10850519 C DBP 0.99 0.30 -0.244 0.04 1.4x10-8 -0.188 0.04 4.7x10-6 327,837 -0.214 0.03 5.1x10-13 
MYH6 14 23761094 rs12050260 T PP 0.97 0.35 0.261 0.05 2.9x10-7 0.132 0.05 4.1x10-3 304,390 0.190 0.03 2.6x10-8 
FURIN-FES 15 91427692 rs138682554 A SBP 0.85 0.03 1.274 0.23 5.1x10-8 0.695 0.21 8.8x10-4 279,876 0.952 0.16 9.8x10-10 
HOXB7 17 46874272 rs585736 A PP 1.00 0.03 0.712 0.13 7.8x10-8 0.517 0.13 4.1x10-5 301,845 0.609 0.09 2.5x10-11 
INSR 19 7258405 rs11671314 C SBP 0.94 0.13 0.532 0.11 8.3x10-7 0.344 0.13 6.2x10-3 253,103 0.452 0.08 3.4x10-8 
JAG1 20 10669188 rs2206815 A PP 0.98 0.50 -0.432 0.05 3.9x10-19 -0.247 0.04 2.7x10-9 324,088 -0.326 0.03 4.7x10-25 
JAG1 20 10767811 rs1040922 T DBP 0.99 0.28 -0.344 0.04 3.8x10-15 -0.156 0.04 1.8x10-4 325,879 -0.245 0.03 4.2x10-16 
PREX1 20 47411149 rs80346118 A DBP 0.99 0.15 -0.305 0.06 3.1x10-8 -0.243 0.05 5.6x10-6 327,614 -0.273 0.04 1.1x10-12 
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CRYAA-SIK1 21 44720890 rs79094191 T DBP 0.98 0.96 -0.691 0.10 3.9x10-11 -0.408 0.12 4.4x10-4 284,734 -0.564 0.08 3.8x10-13 
UK Biobank exome                           
ST7L-CAPZA1-MOV10 1 113456546 rs1049434 A DBP 1.00 0.44 -0.175 0.04 9.7x10-6 -0.131 0.03 1.1x10-5 264,717 -0.147 0.02 6.6x10-10 
CDH17 8 95264265 rs138582164 A PP 0.78 0.001 5.199 0.99 1.3x10-7 2.620 0.73 3.2x10-4 226,592 3.529 0.59 1.7x10-9 
 727 
Locus: For (a) the locus name from Table 1 for the nearest annotated gene, (b) the name of the previously reported blood pressure locus; Pos: build 37; EA: effect allele; 728 
Trait: the validated trait with most significant association in the combined meta-analysis; INFO: imputation quality score; EAF: effect allele frequency from discovery data in 729 
UK Biobank; Beta: effect estimate from linear regression; SE: Standard Error of effect estimate; P: P-value of association; N: total sample size analysed; (Note: within the UK 730 
Biobank discovery analysis the sample size was N=140,882/140,886 for systolic and pulse pressure / diastolic pressure.) 731 
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Figure 1: Study design schematic for discovery and validation of novel loci. N: sample size; QC: 732 
Quality Control; PCA: Principal Component Analysis; BP: blood pressure; SBP: systolic BP; DBP: 733 
diastolic BP; PP: pulse pressure; SNVs: single nucleotide variants; BMI: body mass index; UKB: 734 
UK Biobank; UKBL: UK BiLEVE; GWAS: Genome-wide association study; MAF: Minor Allele 735 
Frequency; P: P-value; LD: Linkage Disequilibrium; 1000G: 1000 Genomes. 736 
 737 
 738 
 739 
  740 
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Figure 2: UK Biobank GWAS discovery Manhattan plots and Venn diagram of 107 novel 741 
validated loci. Plots (A), (B) and (C) show the UK Biobank GWAS discovery circos Manhattan 742 
plots for systolic blood pressure (SBP), diastolic blood pressure (DBP) and pulse pressure (PP) 743 
respectively. P-value results are plotted on a –log10 scale (see legend) for all ~9.8 million 744 
variants with Minor Allele Frequency (MAF) ≥ 1% and imputation quality INFO > 0.1 analysed 745 
within the GWAS discovery. Associations are plotted in red for all variants within validated 746 
novel loci, in black for variants within novel loci which were looked-up (P<1×10
-6
) in replication 747 
data but did not replicate, in blue for all variants within previously reported blood pressure 748 
loci, and grey otherwise. Loci names labelled around the edge are specific to each blood 749 
pressure trait, with red labels corresponding to novel loci validated for the given trait (102 750 
novel loci from Table 1a in total across plots (A-C) from GWAS), and blue labels corresponding 751 
to previously reported loci within which new independent secondary variants were identified 752 
(20 GWAS variants in total from Table 2b). Plot (D) presents a Venn diagram, showing 753 
concordance of significant associations across the three blood pressure phenotypes for the 754 
107 novel sentinel variants (Table 1) from both the GWAS and exome analyses. 755 
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Figure 3: Association of blood pressure loci with other traits. Plot (A) shows results for 799 
associations with other traits which were extracted from the PhenoScanner database for the 800 
sentinel novel variants from Table 1, including proxies in Linkage Disequilibrium (r
2
≥ 0.8), with 801 
genome-wide significant associations (P < 5×10
-8
). The loci are grouped by blood pressure 802 
traits ordered right to left according to the loci in Table 1. There are four systolic blood 803 
pressure associated loci, 14 diastolic blood pressure associated loci and nine pulse pressure 804 
associated loci with associations with other traits reported in the literature. Traits are grouped 805 
into different disease categories: “Pulse/HR” includes pulse, heart rate, pulse wave velocity 806 
and aortic stiffness traits; “CAD/CHD/MI”: Coronary Artery Disease / Coronary Heart Disease 807 
/ Myocardial Infarction; “Blood” traits: Haemoglobin levels and platelet counts; “Lipids”: LDL 808 
and Total Cholesterol; “BMI/WHR” includes Body Mass Index, weight, obesity, waist or hip 809 
circumference, Waist-Hip-Ratio; “Menarche”: age at menarche; “Lung”: lung function (FEV1); 810 
“Alzheimer’s” traits refers to Cerebrospinal fluid levels of Alzheimer’s disease related proteins; 811 
“Cancer” includes carcinomas, neuroblastomas, bladder cancer; “Education”: years of 812 
educational attainment. 813 
Plots (B) and (C) show mouse phenotype enrichment and disease ontology enrichment, 814 
respectively, of novel and previously reported variants. Enrichment was performed using the 815 
GREAT tool (http://bejerano.stanford.edu/great) with the sentinel SNVs as query. 816 
 817 
 818 
 819 
 820 
  821 
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Figure 4: Distribution of a Genetic Risk Score (GRS) based on novel and previously reported 822 
blood pressure variants and its relationship with blood pressure levels, hypertension and 823 
cardiovascular disease (CVD) outcomes. (A): Distribution of GRS in the independent Airwave 824 
study and odds ratio of hypertension at age 50+ comparing each of the upper four GRS 825 
quintiles with the lowest quintile. (B): Mean blood pressures in Airwave study age 50+ across 826 
GRS quintiles. (C): Distribution of GRS in UK Biobank and odds ratio of CVD, Coronary Artery 827 
Disease (CAD) and stroke comparing each of the upper four GRS quintiles with the lowest 828 
quintile. (D) Number of CVD, CAD and stroke outcomes (self-reports, events and deaths) 829 
across GRS quintiles in UK Biobank participants. 830 
 831 
 832 
 833 
  834 
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Figure 5: Summary of novel gene cardiovascular expression. Genes are shown on the basis of 835 
their tissue expression and supporting evidence summarised in Supplementary Table 14, 836 
based on Knockout (KO) phenotype, previously reported blood pressure biology or a strong 837 
functional rationale: eQTL (expression Quantitative Trait Loci), nsSNV (non-synonymous SNV), 838 
Hi-C. Multiple lines of evidence indicate the central importance of the vasculature in blood 839 
pressure regulation and we thus highlight existing drugged (*) and druggable (#) targets 840 
among these genes.  Illustrations used elements with permission from Servier Medical 841 
Art: www.servier.fr/servier-medical-art. 842 
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Online Methods 871 
UK Biobank data 872 
Our Genome Wide Association Study (GWAS) analysis is performed using data from the 873 
interim release of the first ~150k UK Biobank participants (Supplementary Methods)17. These 874 
consist of ~100k individuals from UK Biobank genotyped at ~800,000 single nucleotide 875 
variants (SNVs) with a custom Affymetrix UK Biobank Axiom Array chip66 and ~50k individuals 876 
genotyped with a custom Affymetrix UK BiLEVE Axiom Array chip from the UK BiLEVE study67, 877 
which is a subset of UK Biobank. SNVs were imputed centrally by UK Biobank using a merged 878 
UK10K sequencing + 1000 Genomes imputation reference panel.  879 
Quality control 880 
Following quality control (QC) procedures already carried out centrally by UK Biobank, we 881 
exclude discordant SNVs and samples with QC failures, gender discordance and high 882 
heterozygosity/missingness. We further restrict our data to a subset of individuals of 883 
European ancestry. By applying kmeans clustering to the Principal Component Analysis (PCA) 884 
data a total of N=145,315 Europeans remain. Then we use the kinship data to exclude 1st and 885 
2nd degree relatives, with N=141,647 unrelated individuals remaining. Finally we restrict our 886 
data to non-pregnant individuals with two automated BP measurements available, resulting 887 
in a maximum of N=140,886 individuals for analysis (Supplementary Methods). 888 
Phenotypic data 889 
After calculating the mean systolic and diastolic pressure values from the two blood pressure 890 
measurements, we adjust for medication use by adding 15 and 10 mmHg to systolic and 891 
diastolic pressure, respectively, for individuals reported to be taking blood pressure-lowering 892 
medication (21.4% of individuals)68. Pulse Pressure is calculated as systolic minus diastolic 893 
pressure, according to the medication-adjusted traits. Hypertension, used in secondary 894 
analyses, is defined as: (i) systolic pressure ≥ 140 mmHg, or (ii) diastolic pressure ≥ 90 mmHg, 895 
(iii) or taking blood pressure-lowering medication; otherwise individuals are classified as non-896 
hypertensive. Descriptive summary statistics are provided for all individuals, and stratified by 897 
UK Biobank vs UK BiLEVE participants (Supplementary Table 1).   898 
Analysis models 899 
For the GWAS, we perform linear regression analyses of the three (untransformed) 900 
continuous, medication-adjusted BP traits (systolic, diastolic and pulse pressure) for all 901 
measured and imputed genetic variants in dosage format using SNPTEST software69 under an 902 
additive genetic model. We carry out a similar analysis for the exome content. Each analysis 903 
includes the following covariates: sex, age, age2, body mass index, top ten PCs and a binary 904 
indicator variable for UK Biobank vs UK BiLEVE to adjust for the different genotyping chips. 905 
We also run an association analysis within UK Biobank for validated novel blood pressure SNVs 906 
and hypertension using logistic regression under an additive model with adjustments as 907 
above. There are 76,554 hypertensive cases and the 64,384 remaining participants are 908 
treated as non-hypertensive controls. This sample size is slightly larger than the N=140,866 909 
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used in the main analyses, since participants with only one blood pressure measurement, but 910 
with reported blood pressure-lowering medication, could be included as hypertensive. 911 
Previously reported variants 912 
We compile a list of all SNVs previously reported to be associated with blood pressure 913 
(Supplementary Table 12). This list includes all published SNVs which have been identified 914 
and validated from previous GWAS, CardioMetabochip and exome chip projects10-12. We 915 
augment this list to include all 34,459 SNVs in Linkage Disequilibrium (LD) with the previously 916 
reported SNVs, according to a threshold of r2 ≥ 0.2. Results for all these variants are extracted 917 
for each of the three blood pressure traits, to check previously reported blood pressure 918 
associations in the UK Biobank data, according to whether the sentinel SNV or a variant at the 919 
locus in LD (r2 ≥ 0.2) with it reached nominal significance (P < 0.01) for association with at 920 
least one of the three BP traits. 921 
Replication strategy 922 
We use three independent external data sets for replication (Supplementary Methods). First, 923 
for the GWAS analysis based on advanced 1000 Genomes imputation enhanced by UK10K 924 
data we consider SNVs with MAF ≥ 1% and perform a reciprocal replication exchange with the 925 
International Consortium of Blood Pressure (ICBP) 1000 Genomes meta-analysis (max N = 926 
150,134). The imputation strategy for ICBP 1000 Genomes meta-analysis is based on an 927 
earlier imputation grid for the 1000 Genomes project. In addition, we recruit further cohorts 928 
with 1000 Genomes data which had not contributed to the ICBP-1000 Genomes discovery 929 
meta-analysis: ASCOT-UK (N = 3,803), ASCOT-SC (N = 2,462), BRIGHT (N = 1,791), Generation 930 
Scotland (GS) (N = 9,749), EGCUT (N = 5,468), Lifelines (N = 13,292) and PREVEND (N = 3,619). 931 
This gives a total of N = 190,318 independent replication samples for the GWAS discovery. 932 
Second, because the UK Biobank and UK BiLEVE genotyping chips contain exome content, we 933 
sought replication from two blood pressure exome consortia (European exome consortium 934 
and the Cohorts for Heart and Ageing research in Genome Epidemiology – CHARGE BP exome 935 
consortium), to allow validation of coding variants and variants with lower frequency. The 936 
European exome consortium (N = 161,926) and CHARGE consortium (N = 119,792) give a total 937 
of N = 281,718 independent replication samples for the UK Biobank exome discovery. 938 
 939 
Note that the lookups for GWAS and exome discovery are distinct sets of SNVs. Loci are 940 
assigned sequentially, prioritising the primary GWAS discovery first, then considering any 941 
remaining loci with non-overlapping exome content for replication in the independent exome 942 
replication resources. 943 
 944 
Statistical criteria for replication 945 
For the GWAS discovery, there are ~9.8 million SNVs with MAF ≥ 1% and INFO > 0.1. We 946 
consider for follow-up any SNVs with P < 1x10-6 for any of the three blood pressure traits. For 947 
the exome discovery, there are 149,026 exome SNVs (Supplementary Methods) which were 948 
polymorphic with INFO > 0.1; for follow-up we consider all SNVs with MAF ≥ 0.01% and P < 949 
1x10-5. All such SNVs are annotated to loci according to both an LD threshold of r2 ≥ 0.2 and a 950 
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1Mb interval region (see Supplementary Methods), and signals are classified either as 951 
belonging to novel loci, or being potential secondary signals at previously reported loci. 952 
Selection of variants for follow-up 953 
The sentinel (most significant) SNV from each association signal is selected for follow-up, all 954 
of which are pairwise-independent by LD (r2 < 0.2). For the GWAS discovery, we check that 955 
potential lookup SNVs are covered within the ICBP-1000G replication data (Supplementary 956 
Methods). Of the 235 novel loci containing previously unreported SNVs with MAF ≥ 1%, INFO 957 
> 0.1 and P<1x10-6, 218 are covered, and similarly 100 of the 123 potential secondary SNVs at 958 
51 of the 54 previously reported BP loci are available for follow-up. For the exome discovery, 959 
by following up SNVs with MAF ≥ 0.01%, INFO > 0.1 and P < 1x10-5 across the three blood 960 
pressure traits, we carry forward for replication sentinel SNVs at 22 novel loci, and potential 961 
secondary SNVs at three previously reported loci. We produce locus zoom plots for each of 962 
the lookup variants.  963 
Replication meta-analyses 964 
The replication and combined meta-analyses were perform within METAL software70 using 965 
fixed effects inverse variance weighted meta-analysis (Supplementary Methods). The 966 
combined meta-analysis of both the UK Biobank discovery (N = 140,886) and GWAS 967 
replication meta-analysis (max N = 190,070) include a total maximum sample size of N = 968 
330,956. For the exome combined meta-analysis, we synthesize data from the UK Biobank 969 
discovery exome content (max N=140,866), with the replication dataset from both exome 970 
consortia (total max N=281,718), giving a maximum sample size of N=422,604. 971 
Validation Criteria 972 
In our study a signal is declared validated if it satisfies ALL of the following three criteria:  973 
(i) the sentinel SNV is genome-wide significant (P < 5×10-8) in the combined meta-974 
analysis for any of the three blood pressure traits;  975 
(ii) the sentinel SNV is significant (P < 0.01) in the replication meta-analysis alone for 976 
association with the most significantly associated blood pressure trait from the 977 
combined meta-analysis; 978 
(iii) the sentinel SNV has concordant direction of effect between the UK Biobank 979 
discovery and the replication meta-analysis for the most significantly associated 980 
blood pressure trait from the combined meta-analysis. 981 
Secondary signals  982 
By conditional analysis within UK Biobank data we assess all validated secondary signals from 983 
novel and previously reported loci for independence from the sentinel or previously reported 984 
SNV, respectively (Supplementary Methods). We declare a secondary signal to be 985 
independent of the previously reported SNV if there is less than a 1.5 fold difference between 986 
the main association and conditional association P-values on a –log10 scale, i.e. if –log10(P) / 987 
-log10(P_cond) < 1.5. Note that the lookup criteria already ensure that the secondary variant 988 
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is not in LD (r2 < 0.2) with the previously reported SNV. If more than one SNV in a region is 989 
found to be independent we undertake further rounds of iterative conditional analysis.  990 
Lookups in non-European ancestries 991 
As a secondary analysis, we look up 102 and 5 novel validated SNVs from the UK Biobank-992 
GWAS and exome analyses, respectively, in non-European ancestry samples. These comprise 993 
analysis of East Asian (N = 31,513) and South Asian (N = 33,115) ancestry data from the iGEN-994 
BP consortium13 for the GWAS lookups, and South Asian (N = 25,937), African American (N = 995 
21,488) and Hispanic (N = 4,581) ancestry data from the CHARGE BP exome consortium12 and 996 
CHD+ Exome consortium11, for the exome content lookups (Supplementary Methods). We 997 
carry out a binomial (sign) test based on the number of SNVs with consistent directions of 998 
effect between UK Biobank and each of the non-European ancestry samples. 999 
Monogenic blood pressure gene lookups  1000 
The UK Biobank and UK BiLEVE arrays include some rare coding variants for monogenic 1001 
disorders. We collate a list of all specific mutation variants within genes known to be 1002 
associated with monogenic blood pressure disorders22. Results from the UKB discovery 1003 
association analyses for all three blood pressure traits are extracted for any of these SNVs 1004 
directly covered within the UK Biobank dataset (Supplementary Table 13). Note that a search 1005 
of proxies did not augment the list of available variants, so results are reported for the specific 1006 
variants only. 1007 
Functional analyses 1008 
In order to prioritise associated SNVs, we use an integrative bioinformatics approach to 1009 
collate functional annotation at both the variant and gene level for each SNV within the blood 1010 
pressure loci (all SNVs in LD r2 ≥ 0.8 with the blood pressure-associated SNVs). At the variant 1011 
level we use ANNOVAR71 to obtain comprehensive functional characterisation of variants, 1012 
including gene location, conservation and amino acid substitution impact based on a range of 1013 
prediction tools.  1014 
We use the University of California Santa Cruz (UCSC) genome browser to review sequence 1015 
specific context of SNVs in relation to function, particularly in the Encyclopedia of DNA 1016 
Elements (ENCODE) dataset72. We use the UCSC table browser to annotate SNVs in ENCODE 1017 
regulatory regions.  We evaluate SNVs for impact on putative micro RNA target sites in the 3’ 1018 
un-translated regions (3’UTR) of transcripts by a query of the miRNASNP database73. We 1019 
evaluate all SNVs in LD (r2 ≥ 0.8) with our novel sentinel SNVs for evidence of mediation of 1020 
expression quantitative trait loci (eQTL) in all 44 tissues using the Genotype-Tissue Expression 1021 
(GTEx) database (www.gtexportal.org), in order to identify novel loci which are highly 1022 
expressed, and to highlight specific tissue types which show eQTLs for a large proportion of 1023 
novel loci. We further seek to identify novel loci with the strongest evidence of eQTL 1024 
associations in arterial tissue, in particular. 1025 
At the gene level, we use Ingenuity Pathway Analysis (IPA) software (IPA®,QIAGEN Redwood 1026 
City,www.qiagen.com/ingenuity) to review genes with prior links to blood pressure, based on 1027 
annotation with the “Blood Pressure” Medline Subject Heading (MESH) term which is 1028 
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annotated to 684 genes. We also use IPA to identify genes which interact with blood pressure 1029 
MESH annotated genes, and evaluate genes for evidence of small molecule druggability based 1030 
on queries of Chembl (www.ebi.ac.uk/chembl/) and Drug Gene Interaction database 1031 
(dgidb.genome.wustl.edu). 1032 
We then perform overall enrichment testing across all loci. Firstly, we use DEPICT74 (Data-1033 
driven Expression Prioritized Integration for Complex Traits) to identify highly expressed 1034 
tissues and cells within the blood pressure loci. DEPICT uses a large number of microarrays 1035 
(~37k) to identify cells and tissues where the genes are highly expressed and uses 1036 
precomputed GWAS phenotypes to adjust for co-founding sources. DEPICT provides a P-value 1037 
of enrichment and false discovery rates adjusted P-values for each tissue/cells tested.  1038 
Furthermore, to investigate regulatory regions, we employ a two tiered approach to 1039 
investigate cell type specific enrichment within DNase I sites using FORGE, which tests for 1040 
enrichment of SNVs within DNase I sites in 123 cell types from the Epigenomics Roadmap 1041 
Project and ENCODE75 (Supplementary Methods). Novel sentinel SNVs discovered in our study 1042 
are analysed along with previously reported SNVs and secondary signals (with P-value < 1×10-1043 
4) to evaluate the overall tissue specific enrichment of blood pressure associated variants.  In 1044 
a second analysis we use FORGE (with no LD filter) to investigate directly our curated 1045 
candidate regulatory SNVs for overlap with cell-specific DNase I signals. 1046 
GenomeRunner76 is used to search for enrichment of novel and previously reported sentinel 1047 
SNVs with histone modification mark genomic features (Supplementary Methods). Relevant 1048 
cardiovascular tissue expression is investigated using Fantom5 reference transcript 1049 
expression data (fantom.gsc.riken.jp/5) (Supplementary Methods).   1050 
We use IPA (IPA®,QIAGEN Redwood City,www.qiagen.com/ingenuity) to identify biological 1051 
pathways and transcriptional upstream regulators enriched for genes within the blood 1052 
pressure loci. The transcriptional upstream regulator analysis aims to identify transcription 1053 
factors, compounds, drugs, kinases and other molecules, for which the target is one of the 1054 
blood pressure genes under investigation.  1055 
We query SNVs against PhenoScanner19 to investigate trait pleiotropy, extracting all 1056 
association results with nominal significance at P < 0.05 for full reporting (Supplementary 1057 
Table 14), and then extract genome-wide significant results to highlight the novel loci with 1058 
strongest evidence of association with other traits (Fig. 3a). We also use the Genomic Regions 1059 
Enrichment of Annotations Tool (GREAT) to study gene set enrichment of mouse phenotype 1060 
and disease ontology terms within our novel and previously reported loci, using default SNV 1061 
to gene mapping settings77.    1062 
We carry out metabolomics analysis using two sets of data. First we use 1H NMR lipidomics 1063 
data on plasma from a subset of 2,000 participants of the Airwave Health Monitoring 1064 
Study78,79 (Supplementary Methods). For each replicated blood pressure-associated SNV we 1065 
ran association tests with the lipidomics data using linear regression analyses, adjusted for 1066 
age and sex. We computed significance thresholds using a permutation derived family wise 1067 
error rate (5%) to account for the high correlation structure of these data (ENT=35)80. We also 1068 
test each replicated SNV against published genome-wide vs metabolome-wide associations 1069 
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in plasma and urine using publicly available data from the “Metabolomics GWAS Server” to 1070 
identify metabolites that have been associated with variants of interest at P < 3.0 x 10-4 1071 
(Bonferroni corrected P for validated signals)25,26. 1072 
Experimental methods 1073 
We prioritise novel genes for laboratory testing on the basis of evidence for SNV function 1074 
(including coding variants, eQTLs and Hi-C interactions), biological support for relevance to 1075 
blood pressure (from literature review) and transgenic phenotype. We perform genotyping 1076 
and Quantitative Reverse-Transcription Polymerase Chain Reaction (q RT-PCR) for the 1077 
selected sentinel variants of interest using human vascular smooth muscle cells and 1078 
endothelial cells and test for expression levels (Supplementary Methods). 1079 
Genetic risk scores  1080 
First, by calculating genetic risk scores (GRS), we use the Airwave study78 data to assess the 1081 
effect in an independent cohort of the blood pressure-associated variants on blood pressure 1082 
and risk of hypertension (Supplementary Methods). This provides an estimate of the 1083 
combined effect of the blood pressure raising variants avoiding bias by “winners curse”. We 1084 
create three trait-specific weighted GRSs (i.e. systolic, diastolic and pulse pressure), for all 1085 
pairwise-independent, LD-filtered (r2 < 0.2) previously reported variants and validated novel 1086 
variants (sentinel and secondary SNVs) combined, using SNVs available in Airwave 1087 
(Supplementary Table 20). For the previously reported variants, we weight blood pressure 1088 
increasing alleles by the trait-specific beta coefficients from the UK Biobank discovery GWAS. 1089 
For the novel variants, beta coefficients of the replication meta-analysis for each blood 1090 
pressure trait are used as independent, unbiased weights.  1091 
For risk score analyses we derive an average blood pressure GRS, as the average of the systolic 1092 
and diastolic pressure GRSs. We standardize the GRS to have mean of zero and standard 1093 
deviation of one. We assess the association of the continuous GRS variable with 1094 
corresponding blood pressure trait by simple linear regression. We also run a logistic 1095 
regression to examine the association of each GRS with risk of hypertension. We perform each 1096 
analysis both with and without adjustment for sex, for comparison. We compare blood 1097 
pressure levels and risk of hypertension for individuals in the top and bottom 20% of the GRS 1098 
distribution at ages 50 years and over using linear and logistic regression, respectively. 1099 
To calculate the percent of variance for each blood pressure trait explained by its 1100 
corresponding trait-specific GRS, not accounted for by known factors, we generate the 1101 
residuals from the regression model of each trait against covariates of age, age-square, sex 1102 
and body mass index. We then fit a second linear model for the trait residuals with all the 1103 
variants in the GRS plus the top 10 principal components. Within the Airwave study, these 1104 
percentage variance explained results are calculated within an independent population. 1105 
We also assess the association of the GRSs with cardiovascular outcomes in the UK Biobank 1106 
data, based on self-reported medical history, and linkage to hospitalization and mortality 1107 
data. We include all pairwise-independent previously reported blood pressure variants and 1108 
validated novel variants. We use logistic regression with binary outcome variables for 1109 
39 
 
coronary heart disease, stroke and cardiovascular disease (see Supplementary Methods) and 1110 
GRS as explanatory variable (with and without sex adjustment).  1111 
 1112 
 1113 
URLs 1114 
FORGE (accessed 16 Aug 2016), 1115 
http://browser.1000genomes.org/Homo_sapiens/UserData/Forge?db=core 1116 
Fantom5 data (accessed 16 Aug 2016), http://fantom.gsc.riken.jp/5/ 1117 
ENCODE DNase I data (wgEncodeAwgDnaseMasterSites; accessed 20 Aug 2016 using Table 1118 
browser) 1119 
ENCODE cell type data (accessed 20 Aug 2016), 1120 
http://genome.ucsc.edu/ENCODE/cellTypes.html. 1121 
Exome chip design: 1122 
http://genome.sph.umich.edu/wiki/Exome_Chip_Design 1123 
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